Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China. The company produces and sells various transformer products, such as power, rectifier, and special transformers for use in metal smelting, electrochemistry, and power grid companies; and manufactures and sells electronic components, including displacement sensors, brake resistance boxes, radio frequency components, resistors, potentiometers, and others for use in aviation, aerospace, weapons, ships, AI intelligence, new energy, rail transit, communications, smart grids, instrumentation and other fields. It also offers animal products, and monoclonal antibody and targeted drugs, as well as drugs for the treatment of cancer and other diseases; laboratory equipment; and CRO, CAR-T technology and stem cell technology research and development, malignant cancer immune cell technology, and genetic testing services. The company also exports its products. The company was formerly known as Beihai Yinhe Industry Investment Co., Ltd. and changed its name to Galaxy Biomedical Investment Co., Ltd. in October 2015. Galaxy Biomedical Investment Co., Ltd. was founded in 1993 and is headquartered in Beihai, China.

Mr. Shu Jian  Zhao

Fin.r Director

Mr. Keyang  Liu

Sec. of the Board & Chairman

Mr. Anjun  Lu

Pres

Ms. Shaolin  Su

Sec. of the Board

Mr. Jian  Huang

Executive Chief Exec. Officer

Mr. De Bin  Ye

Executive Vice President

Chief Engineer & Executive Vice President

Executive Vice President & Director

Mr. Yuan Hong  Lu

Vice President & Chief Financial Officer

Elektronische Komponenten

Galaxy Biomedical Investment Co., Ltd.

Galaxy Biomedical Investment Co., Ltd. Management-Struktur

Informationen zum Management